Ignyta, Inc.
RXDX evidence brief
What we can confirm
- BioSniper Score:
- 3.7 / 10
- Lead Asset:
- taladegib (Phase 1)
What it means
What to watch
Prepared research question
What matters most for RXDX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
taladegib (Phase 1)
Next Catalyst
—
Tracking 1 pipeline candidate for Ignyta, Inc..
Run Ignyta, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Ignyta, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 1
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Governance
Frequently asked questions
What is Ignyta, Inc.'s lead drug candidate?
Ignyta, Inc.'s most advanced tracked candidate is taladegib (Phase 1) for solid tumors.
Who is the CEO of Ignyta, Inc.?
Jonathan E. Lim, M.D. is the chief executive officer of Ignyta, Inc. (RXDX).
What therapeutic areas does Ignyta, Inc. focus on?
Ignyta, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.